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Case Report
Vancomycin and Gentamicin Pharmacokinetic Alterations in an 
Adolescent Amputee
Kristen R. Nichols, PharmD,1,2,3 Kari M. Edison, PharmD,1 Michelle D. Rosenbaum, PharmD,1 
and Chad A. Knoderer, PharmD1,2,3
1Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis, 
Indiana, 2Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana, 
3Department of Pediatrics, Ryan White Center for Pediatric Infectious Disease, Indiana University School of Medicine, 
Indianapolis, Indiana
A 14-year-old male with bilateral above-the-knee amputations presented to our hospital for treatment of 
a skin and soft-tissue infection. We report the experience of vancomycin and gentamicin therapy in this 
patient. Because these medications require weight-based dosages and pharmacokinetic monitoring of 
serum levels, it was necessary to obtain peak and trough levels of the two drugs in order to determine the 
pharmacokinetic differences in this patient compared to those in an adolescent male without amputations. 
To our knowledge, this is the first report describing pharmacokinetic differences in an adolescent amputee.
INDEX TERMS adolescent, amputee, gentamicin, pharmacokinetics, vancomycin
J Pediatr Pharmacol Ther 2013;18(1):63–66
INTRODUCTION
Vancomycin and aminoglycoside dosages in 
children can be challenging because of develop-
mental pharmacologic changes and pharmacoki-
netic differences observed in children compared 
to those in adults.1 While generally uncommon, 
pediatric amputees represent a population for 
which, to our knowledge, no published reports 
describe pharmacokinetic alterations or provide 
specific dosing recommendations. We report 
pharmacokinetic alterations observed with van-
comycin and gentamicin in an adolescent ampu-
tee and discuss considerations for pharmacists.
CASE REPORT
A 14-year-old (46.4 kg, 135 cm) Caucasian male 
presented to the hospital with redness, swelling, 
and serosanguinous drainage from the second 
digit on his left hand 3 days after sustaining an 
injury. It was reported that swelling and redness 
spread to the dorsal portion of the finger 2 days 
after the incident. The patient has a medical his-
tory significant for attention deficit hyperactivity 
disorder, bipolar disorder, congenital insensitiv-
ity to pain, and bilateral above-the- knee amputa-
tions (AKA; left lower extremity in 2006 and right 
lower extremity in 2008) because of recurrent 
lower extremity infections.
Upon hospital admission, vancomycin, 690 mg 
(15 mg/kg/dose) intravenous (IV) every 8 hours; 
clindamycin, 460 mg (10 mg/kg/dose) IV every 8 
hours; and gentamicin, 140 mg (3 mg/kg/dose) 
IV every 24 hours were empirically initiated for 
activity against methicillin-susceptible and -re-
sistant Staphylococcus aureus (MSSA and MRSA, 
respectively) infection and group A Streptococcus 
spp infection. Blood and wound cultures were 
obtained on the day of admission and prior to 
antibacterial initiation. The wound culture sub-
sequently grew MRSA and Streptococcus pyogenes, 
while the blood culture revealed Streptococcus 
pyogenes (susceptibility tests were not performed 
secondary to the rare occurrence of antimicrobial 
resistance in this organism). The vancomycin 
minimum inhibitory concentration for the MRSA 
was ≤0.5 mg/L. The patient’s serum creatinine 
(SCr) concentration upon antibiotic initiation 
was within the institution’s normal limits for the 
patient’s age at 0.53 mg/dL.
Due to the amputation history and potential 
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for altered pharmacokinetic parameters, trough 
and peak concentrations of both vancomycin and 
gentamicin were obtained. It was suspected that 
the patient might have had an altered volume 
of distribution (Vd) for each drug and that his 
SCr concentration might not have adequately 
reflected drug clearance due to his limited mo-
bility and lean adipose tissue. Concentrations 
and calculated parameters are described in the 
Table. Gentamicin pharmacokinetic parameters 
could not be completely calculated due to the 
reported trough concentration of less than 0.5 
mg/L, which is the lower limit of detection at 
our institution’s laboratory.
After final organism identification and suscep-
tibility testing, gentamicin was discontinued. The 
vancomycin dose was increased to 750 mg every 
8 hours to target a goal trough serum concentra-
tion of 10 to 15 mg/L. The patient received a total 
of 10 days of antibiotic therapy, including clinda-
mycin monotherapy (450 mg IV every 6 hours) 
for the final 3.5 hospital days. Blood cultures were 
consistently negative after the original positive 
culture on the day of admission.
DISCUSSION
Limited pharmacokinetic data available for the 
amputee population makes drug dosages a sig-
nificant challenge. Specifically, current literature 
on vancomycin or aminoglycoside dosages in 
pediatric amputees is not available. While there 
are a small number of resources available for 
determining body surface area and preamputa-
tion body weight in adults with lower limb am-
putations, there is currently no correlation to the 
pediatric population.2,3 The 14-year-old patient 
in this case report represented a unique dosage 
challenge because of general pharmacokinetic 
differences that can be observed in children and 
adolescents in addition to potential distribution 
volume alterations related to his amputations.
Actual body weight is used to calculate ami-
noglycoside doses for pediatric patients, unless 
the patient weighs more than 125% of their 
ideal body weight (IBW), in which case a dos-
ing weight is recommended based on standard 
adult practice.4 Actual body weight is also used 
for vancomycin dosages.5 Our patient weighed 
46.4 kg, reflecting a normal weight for a typical 
14-year-old male. His amputation status made 
calculation of his true IBW and ultimately drug 
dosage difficult. Furthermore, a method for 
determining the adjusted or dosage weight for 
aminoglycosides in pediatric amputees is not 
available. As pharmacists, it is imperative to 
thoroughly review each patient’s medical records 
for pertinent history and physical examination 
findings and even to visualize each patient in 
whom vancomycin or aminoglycosides is to be 
administered. Important insights can be gained 
by observing the patient.
Each of the drug serum concentrations were 
obtained to determine drug clearance and vol-
ume of distribution and to determine whether 
efficacy and safety concentration targets were 
met. The gentamicin peak serum concentration 
was higher than necessary for synergy (3 to 5 
Table. Calculated Pharmacokinetic Parameters and Monitoring
Parameter Vancomycin Gentamicin
Dosage 690 mg every 8 hr 140 mg every 24 hr
mg/kg/dose 15 mg/kg/dose 3 mg/kg/dose
Dose at which concentrations were obtained Fifth Second
Peak serum concentration (corrected) 43.2 (49.2) mg/L 10.8 mg/L
Time to peak obtained in relation to dose 30 min after 2-hr infusion 1 hr after 30-min infusion
Trough serum concentration (corrected) 8.4 (10.2) mg/L < 0.5 mg/L
Time to trough obtained in relation to dose 8 hr and 45 min after last dose 23 hr and 40 min after last dose
Rate of elimination (Ke) 0.262 hr
−1 *
Vd (L/kg) 0.27 L/kg 0.28 L/kg 
Elimination half-life 2.6 hr *
Ke, eliminate rate; Vd, volume of distribution
*Could not be accurately calculated as serum concentration values were below the lower limit of detectability.
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mg/L is our institution standard).6 We posit 
that the elevated concentration was caused by 
a slightly decreased Vd value resulting from the 
amputations, relative to those of normal pedi-
atric levels.7 The true volume of distribution is 
likely slightly lower than the calculated value 
of 0.28 L/kg, as the serum concentration was 
obtained 1 full hour (compared to 30 minutes) 
following the end of a 30-minute infusion. The 
“peak” serum concentration may also be higher 
than expected because the patient was given a 
3 mg/kg/dose based on his actual rather than 
an adjusted weight. While renal dysfunction 
would not be expected in an otherwise normal 
adolescent with bilateral AKA, SCr level may not 
be the most useful indication of renal function 
because of decreased muscle mass and mobility. 
The patient’s undetectable gentamicin trough 
serum concentration suggested adequate renal 
gentamicin clearance.
This patient’s therapy was initiated with 15 
mg/kg of vancomycin every 8 hours, which is 
an appropriate empirical dose for a 14-year-old 
patient with normal renal function. The subse-
quent peak serum concentration was higher than 
anticipated given the dose administered and was 
most likely due to a calculated vancomycin Vd of 
0.27 L/kg, which is lower than that expected for 
an adolescent. Typical “normal” values originate 
mostly from younger patients with a mean age 
of 7 years.8 Reported pediatric vancomycin Vd 
values range from 0.43 L/kg to 0.63 L/kg.8−10 It 
is difficult to determine whether the low Vd value 
in our patient was caused by normal variation 
or was secondary to the amputation, and unfor-
tunately, no values for adult amputees could be 
found in the literature. Although the vancomycin 
trough serum concentration was not drawn at 
the correct time, the patient’s calculated true 
trough serum concentration of 10.2 mg/L was 
close to the recommended minimum value of 10 
mg/L.11 However, to ensure a trough concentra-
tion within a target range of 10 to 15 mg/L, the 
dose was increased. Further concentrations were 
not obtained as it could be reasonably expected 
that the change in dose would result in trough 
concentration within the target range.
The cost of serum concentrations should be a 
consideration when caring for unique patients. 
At our institution, patients are charged approxi-
mately $150 for each serum concentration. While 
peak vancomycin concentrations are generally 
not advocated because of the lack of correlation 
with efficacy, it was justified in this case in order 
to determine patient-specific pharmacokinetic 
parameters.11 A peak gentamicin concentration 
was also obtained to determine pharmacoki-
netic parameters. In an otherwise healthy child, 
neither the vancomycin nor the gentamicin peak 
concentrations would have been obtained at our 
institution. It was believed that the benefit of 
using peak concentrations to calculate pharma-
cokinetic parameters in our adolescent amputee 
outweighed the additional charge.
CONCLUSIONS
This case report is the first to describe serum 
concentrations and pharmacokinetic altera-
tions with vancomycin or aminoglycosides in 
an adolescent amputee and offers a reminder 
to pharmacists practicing with unique patient 
populations. While population pharmacokinetic 
data and medical guidelines aid in optimal vanco-
mycin and gentamicin drug doses in a relatively 
robust group of patients, those cannot replace the 
evaluative process pharmacists must consistently 
perform to adequately ensure optimal doses in 
all populations. Pharmacists must work to find 
a balance between evidence-based guidelines or 
standards of care and the need to use serum drug 
monitoring to optimize drug efficacy and safety.
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